Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement: Results From the PREMIER Registry
By J. Spertus, R. Kettelkamp, C. Vance, C. Decker, Philip G. Jones, J. Rumsfeld, J. Messenger, S. Khanal, E. Peterson, R. Bach and 2 more. Circulation, 2006
852 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/27c7bda4d6b3722be08ad2d07bf51167c9218e12
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Surgery
Citations in the corpus
- Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D (2007, methodology): “In an analysis from the PRE-MIER registry ( 19 ), factors identified with premature discontinuation of thienopyridine therapy included older age, not having completed high school, not being married, not receiving discharge instructions for medication use, not being referred for cardiac rehabilitatio”
- Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. (2007, background): “Premature discontinuation of this minimum antiplatelet therapy has been associated with stent thrombosis.(4,5) However, studies of late thrombosis events among patients with a drug-eluting stent have cast doubt on whether the recommended regimens are sufficient.”